- call +1-201-465-4211
- email sales@mrinsights.biz
Monoclonal antibodies are antibodies that are made by identical immune cells that are all clones of a unique parent cell. Monoclonal antibodies can have monovalent affinity, in that they bind to the same epitope (the part of an antigen that is recognized by the antibody). In contrast, polyclonal antibodies bind to multiple epitopes and are usually made by several different plasma cell (antibody secreting immune cell) lineages.
Scope of the Report:
This report studies the Monoclonal Antibody Therapy market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Monoclonal Antibody Therapy market by product type and applications/end industries.
Therapeutic monoclonal antibodies act through multiple mechanisms, such as blocking of targeted molecule functions, inducing apoptosis in cells which express the target, or by modulating signaling pathways. One possible treatment for cancer involves monoclonal antibodies that bind only to cancer cell-specific antigens and induce an immune response against the target cancer cell.In addition, monoclonal antibodies used for autoimmune diseases include infliximab and adalimumab, which are effective in rheumatoid arthritis, Crohn's disease, ulcerative colitis and ankylosing spondylitis by their ability to bind to and inhibit TNF-α.
The global Monoclonal Antibody Therapy market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Monoclonal Antibody Therapy.
Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.
Market Segment by Companies, this report covers
Abbvie
Amgen
Glaxosmithkline
Merck
Novartis
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Recombinant
Chimeric
Humanized
Human
Market Segment by Applications, can be divided into
Diagnostic Test
Analytical And Chemical Uses
Cancer Treatment
Autoimmune Diseases
Hematological Disorders
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Monoclonal Antibody Therapy Market Overview
1.1 Product Overview and Scope of Monoclonal Antibody Therapy
1.2 Classification of Monoclonal Antibody Therapy by Types
1.2.1 Global Monoclonal Antibody Therapy Revenue Comparison by Types (2017-2023)
1.2.2 Global Monoclonal Antibody Therapy Revenue Market Share by Types in 2017
1.2.3 Recombinant
1.2.4 Chimeric
1.2.5 Humanized
1.2.6 Human
1.3 Global Monoclonal Antibody Therapy Market by Application
1.3.1 Global Monoclonal Antibody Therapy Market Size and Market Share Comparison by Applications (2013-2023)
1.3.2 Diagnostic Test
1.3.3 Analytical And Chemical Uses
1.3.4 Cancer Treatment
1.3.5 Autoimmune Diseases
1.3.6 Hematological Disorders
1.4 Global Monoclonal Antibody Therapy Market by Regions
1.4.1 Global Monoclonal Antibody Therapy Market Size (Million USD) Comparison by Regions (2013-2023)
1.4.1 North America (USA, Canada and Mexico) Monoclonal Antibody Therapy Status and Prospect (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy) Monoclonal Antibody Therapy Status and Prospect (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Monoclonal Antibody Therapy Status and Prospect (2013-2023)
1.4.4 South America (Brazil, Argentina, Colombia) Monoclonal Antibody Therapy Status and Prospect (2013-2023)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Monoclonal Antibody Therapy Status and Prospect (2013-2023)
1.5 Global Market Size of Monoclonal Antibody Therapy (2013-2023)
2 Manufacturers Profiles
2.1 Abbvie
2.1.1 Business Overview
2.1.2 Monoclonal Antibody Therapy Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Abbvie Monoclonal Antibody Therapy Revenue, Gross Margin and Market Share (2016-2017)
2.2 Amgen
2.2.1 Business Overview
2.2.2 Monoclonal Antibody Therapy Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Amgen Monoclonal Antibody Therapy Revenue, Gross Margin and Market Share (2016-2017)
2.3 Glaxosmithkline
2.3.1 Business Overview
2.3.2 Monoclonal Antibody Therapy Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Glaxosmithkline Monoclonal Antibody Therapy Revenue, Gross Margin and Market Share (2016-2017)
2.4 Merck
2.4.1 Business Overview
2.4.2 Monoclonal Antibody Therapy Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Merck Monoclonal Antibody Therapy Revenue, Gross Margin and Market Share (2016-2017)
2.5 Novartis
2.5.1 Business Overview
2.5.2 Monoclonal Antibody Therapy Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Novartis Monoclonal Antibody Therapy Revenue, Gross Margin and Market Share (2016-2017)
3 Global Monoclonal Antibody Therapy Market Competition, by Players
3.1 Global Monoclonal Antibody Therapy Revenue and Share by Players (2013-2018)
3.2 Market Concentration Rate
3.2.1 Top 5 Monoclonal Antibody Therapy Players Market Share
3.2.2 Top 10 Monoclonal Antibody Therapy Players Market Share
3.3 Market Competition Trend
4 Global Monoclonal Antibody Therapy Market Size by Regions
4.1 Global Monoclonal Antibody Therapy Revenue and Market Share by Regions
4.2 North America Monoclonal Antibody Therapy Revenue and Growth Rate (2013-2018)
4.3 Europe Monoclonal Antibody Therapy Revenue and Growth Rate (2013-2018)
4.4 Asia-Pacific Monoclonal Antibody Therapy Revenue and Growth Rate (2013-2018)
4.5 South America Monoclonal Antibody Therapy Revenue and Growth Rate (2013-2018)
4.6 Middle East and Africa Monoclonal Antibody Therapy Revenue and Growth Rate (2013-2018)
5 North America Monoclonal Antibody Therapy Revenue by Countries
5.1 North America Monoclonal Antibody Therapy Revenue by Countries (2013-2018)
5.2 USA Monoclonal Antibody Therapy Revenue and Growth Rate (2013-2018)
5.3 Canada Monoclonal Antibody Therapy Revenue and Growth Rate (2013-2018)
5.4 Mexico Monoclonal Antibody Therapy Revenue and Growth Rate (2013-2018)
6 Europe Monoclonal Antibody Therapy Revenue by Countries
6.1 Europe Monoclonal Antibody Therapy Revenue by Countries (2013-2018)
6.2 Germany Monoclonal Antibody Therapy Revenue and Growth Rate (2013-2018)
6.3 UK Monoclonal Antibody Therapy Revenue and Growth Rate (2013-2018)
6.4 France Monoclonal Antibody Therapy Revenue and Growth Rate (2013-2018)
6.5 Russia Monoclonal Antibody Therapy Revenue and Growth Rate (2013-2018)
6.6 Italy Monoclonal Antibody Therapy Revenue and Growth Rate (2013-2018)
7 Asia-Pacific Monoclonal Antibody Therapy Revenue by Countries
7.1 Asia-Pacific Monoclonal Antibody Therapy Revenue by Countries (2013-2018)
7.2 China Monoclonal Antibody Therapy Revenue and Growth Rate (2013-2018)
7.3 Japan Monoclonal Antibody Therapy Revenue and Growth Rate (2013-2018)
7.4 Korea Monoclonal Antibody Therapy Revenue and Growth Rate (2013-2018)
7.5 India Monoclonal Antibody Therapy Revenue and Growth Rate (2013-2018)
7.6 Southeast Asia Monoclonal Antibody Therapy Revenue and Growth Rate (2013-2018)
8 South America Monoclonal Antibody Therapy Revenue by Countries
8.1 South America Monoclonal Antibody Therapy Revenue by Countries (2013-2018)
8.2 Brazil Monoclonal Antibody Therapy Revenue and Growth Rate (2013-2018)
8.3 Argentina Monoclonal Antibody Therapy Revenue and Growth Rate (2013-2018)
8.4 Colombia Monoclonal Antibody Therapy Revenue and Growth Rate (2013-2018)
9 Middle East and Africa Revenue Monoclonal Antibody Therapy by Countries
9.1 Middle East and Africa Monoclonal Antibody Therapy Revenue by Countries (2013-2018)
9.2 Saudi Arabia Monoclonal Antibody Therapy Revenue and Growth Rate (2013-2018)
9.3 UAE Monoclonal Antibody Therapy Revenue and Growth Rate (2013-2018)
9.4 Egypt Monoclonal Antibody Therapy Revenue and Growth Rate (2013-2018)
9.5 Nigeria Monoclonal Antibody Therapy Revenue and Growth Rate (2013-2018)
9.6 South Africa Monoclonal Antibody Therapy Revenue and Growth Rate (2013-2018)
10 Global Monoclonal Antibody Therapy Market Segment by Type
10.1 Global Monoclonal Antibody Therapy Revenue and Market Share by Type (2013-2018)
10.2 Global Monoclonal Antibody Therapy Market Forecast by Type (2018-2023)
10.3 Recombinant Revenue Growth Rate (2013-2023)
10.4 Chimeric Revenue Growth Rate (2013-2023)
10.5 Humanized Revenue Growth Rate (2013-2023)
10.6 Human Revenue Growth Rate (2013-2023)
11 Global Monoclonal Antibody Therapy Market Segment by Application
11.1 Global Monoclonal Antibody Therapy Revenue Market Share by Application (2013-2018)
11.2 Monoclonal Antibody Therapy Market Forecast by Application (2018-2023)
11.3 Diagnostic Test Revenue Growth (2013-2018)
11.4 Analytical And Chemical Uses Revenue Growth (2013-2018)
11.5 Cancer Treatment Revenue Growth (2013-2018)
11.6 Autoimmune Diseases Revenue Growth (2013-2018)
11.7 Hematological Disorders Revenue Growth (2013-2018)
12 Global Monoclonal Antibody Therapy Market Size Forecast (2018-2023)
12.1 Global Monoclonal Antibody Therapy Market Size Forecast (2018-2023)
12.2 Global Monoclonal Antibody Therapy Market Forecast by Regions (2018-2023)
12.3 North America Monoclonal Antibody Therapy Revenue Market Forecast (2018-2023)
12.4 Europe Monoclonal Antibody Therapy Revenue Market Forecast (2018-2023)
12.5 Asia-Pacific Monoclonal Antibody Therapy Revenue Market Forecast (2018-2023)
12.6 South America Monoclonal Antibody Therapy Revenue Market Forecast (2018-2023)
12.7 Middle East and Africa Monoclonal Antibody Therapy Revenue Market Forecast (2018-2023)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
List of Tables and Figures
Figure Monoclonal Antibody Therapy Picture
Table Product Specifications of Monoclonal Antibody Therapy
Table Global Monoclonal Antibody Therapy and Revenue (Million USD) Ma
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
